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Abstract
Background: Low back pain is a major clinical and public health problem, with limited evidence-based treatments.
Low-dose antidepressants are commonly used to treat pain in chronic low back pain. However, their efficacy is
unproven. The aim of this pragmatic, double-blind, randomised, placebo-controlled trial is to determine whether
low-dose amitriptyline (an antidepressant) is more effective than placebo in reducing pain in individuals with
chronic low back pain.
Methods/design: One hundred and fifty individuals with chronic low back pain will be recruited through hospital
and private medical and allied health clinics, advertising in local media and posting of flyers in community
locations. They will be randomly allocated to receive either low-dose amitriptyline (25 mg) or an active placebo
(benztropine mesylate, 1 mg) for 6 months. The primary outcome measure of pain intensity will be assessed at
baseline, 3 and 6 months using validated questionnaires. Secondary measures of self-reported low back disability,
work absence and hindrance in the performance of paid/unpaid work will also be examined. Intention-to-treat
analyses will be performed.
Discussion: This pragmatic, double-blind, randomised, placebo-controlled trial will provide evidence regarding the
effectiveness of low-dose antidepressants compared with placebo in reducing pain, disability, work absenteeism
and hindrance in work performance in individuals with chronic low back pain. This trial has major public health and
clinical importance as it has the potential to provide an effective approach to the management of chronic low back
pain.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12612000131853; registered on 30 January 2012.
Keywords: Antidepressants, Low back pain, Pain, Randomised controlled trial, Amitriptyline
Background
Low back pain is a major public health problem worldwide.
It is one of the most widespread health conditions, with a
lifetime prevalence of more than 70 % in industrialised
countries [1]. It is also the leading cause of disability
globally, with estimates indicating that it is responsible for
83 million years lived with disability [2]. Moreover, low back
pain is associated with substantial socioeconomic burden
due to disability and productivity losses, with annual costs
of AU$9.17 billion in Australia [3] and US$91 billion in the
United States [4]. Although low back pain results in huge
personal and socioeconomic costs, effective evidence-based
treatments are limited.
Drug therapy is one of the treatment options available
for chronic low back pain. Antidepressants are com-
monly prescribed in low back pain to treat depression,
sleep and pain and their use is increasing for the
* Correspondence: Donna.Urquhart@monash.edu
1Department of Epidemiology and Preventive Medicine, School of Public
Health and Preventive Medicine, Monash University, Alfred Hospital,
Melbourne, VIC 3004, Australia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Urquhart et al. Trials  (2016) 17:514 
DOI 10.1186/s13063-016-1637-1
treatment of low back pain [5]. Two main groups of an-
tidepressants are used in the treatment of low back pain,
tricyclic antidepressants (TCAs) and selective serotonin
reuptake (SSRIs) inhibitors. While the mechanism of
action of these antidepressants is not fully understood,
their effect is attributed to inhibition of the reuptake of
serotonin and/or noradrenaline in the central nervous
system [6]. However, there is evidence to indicate that
TCAs and SSRIs have an effect on the endogenous
opioid system and can also act peripherally [7]. These
mechanisms are thought to be important in targeting
central sensitisation in chronic low back pain, where an
abnormal state of responsiveness or increased gain in the
nociceptive system occurs and neurons activated by noci-
ceptive stimulus are sensitised and become hyperrespon-
sive to subsequent stimuli [8]. Thus, antidepressants, at
significantly lower doses (25–50 mg) than those which are
used for depression (100–300 mg) are used in clinical
practice to treat pain [6, 9]. In addition, the analgesic effect
of low-dose antidepressants has been shown to be
independent of their mood-altering effect [10].
Several systematic reviews have examined the efficacy of
antidepressants in the management of chronic low back
pain [11–13]. However, these reviews have reached different
conclusions. A Cochrane systematic review and meta-
analysis, which evaluated the effectiveness of TCAs (seven
studies), SSRIs (three studies) and ‘atypical’ antidepressants
(two studies), concluded that there is no clear evidence to
indicate that antidepressants are more effective than pla-
cebo in reducing pain in individuals with chronic low back
pain [14]. Moreover, pooled analyses showed no difference
in pain relief between different types of antidepressants and
placebo. However, a high-quality trial by Atkinson [15],
which performed a head-to-head comparison of TCAs and
SSRIs, reported a greater reduction in pain intensity with a
low concentration of a TCA than with all concentrations of
a SSRI. The authors concluded that the Cochrane review
was limited by a paucity of trials, in particular those exam-
ining low-dose antidepressants, small study populations
and variation in study quality and individuals recruited.
Further trials were recommended to confirm the efficacy of
antidepressant therapy for chronic low back pain. Thus, the
role of antidepressants in low back pain is unclear and al-
though low-dose antidepressants are a common treatment
for chronic low back pain, their use is still unproven for the
treatment of pain.
We propose a pragmatic, double-blind, randomised,
placebo-controlled trial to determine whether a low-dose
TCA (amitriptyline) is effective in reducing pain. It is
hypothesised that low-dose amitriptyline will improve pain
in individuals with chronic low back pain. If it is found to
be effective, it will provide high-quality evidence for its use
and potentially enable this treatment option to be consid-
ered by more individuals with chronic low back pain. If we
do not find low-dose amitriptyline to be effective, then our
trial will provide strong evidence to reconsider its use in
the management of chronic low back pain.
Methods
Study design
This study is a double-blind, randomised, placebo-
controlled trial, with a two-arm, parallel group, superiority
design. The trial was registered at the Australian New
Zealand Clinical Trials Registry prior to recruitment
(ACTRN: ACTRN12612000131853) and trial reporting
will be guided by the Consolidated Standards of Reporting
Trials (CONSORT) [16] and Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines (See Additional file 1). Ethics approval has been
obtained from the Alfred Hospital Ethics Committee
(HREC/12/Alfred/16, 476/11), Monash University Human
Research Ethics Committee (CF12/0271 - 2012000106)
and the Eastern Health Human Ethics Committee
(SERP28/1112).
Participants
A total of 150 individuals with chronic low back pain will
be recruited through hospital and private medical and allied
health clinics, advertising in local media including national
newspapers and community magazines, and posting of
flyers in community locations such as shops, libraries and
medical clinics. Written informed consent will be obtained
from all participants by research staff trained in study
procedures specific to this trial.
Inclusion criteria
We will recruit male and female participants aged 18–75
years with chronic, nonspecific low back pain, which is
defined as pain between the lower borders of the rib
cage and the gluteal folds, is without a specific cause
and has been present for longer than 3 months [17, 18].
Exclusion criteria
Participants with any of the following will be excluded: (1)
specific pathological entity, such as infection, metastasis,
osteoporosis or fractures, (2) major coexisting illness
which might confound assessment of function or for
which amitriptyline may be inappropriate (e.g. heart or
thyroid problems, glaucoma, seizures, urinary issues), (3)
another significant musculoskeletal condition, (4) history
of psychosis, (5) current or previously diagnosed depres-
sion with or without the use of medication), (6) any prior
or current use of antidepressants, (7) current use of opi-
oids, (8) any contraindication or allergy to amitriptyline,
(9) pregnancy, planning or trying to become pregnant or
breastfeeding or (10) inability to give informed consent,
including individuals that are unable to read, speak or
understand English.
Urquhart et al. Trials  (2016) 17:514 Page 2 of 8
Randomisation and blinding
Randomisation will be based on computer-generated
random numbers prepared by a statistician who will have
no involvement in the trial. The allocation of participants
will be in a 1:1 ratio to either the intervention or the
control group. The use of a central allocation which
involves pharmacy-controlled randomisation will ensure
that the allocation cannot be accessed or influenced by
any of the research personnel. The randomised controlled
trial (RCT) will be double-blinded, with both participants
and investigators assessing outcomes blinded to treatment
allocation. Allocation concealment and double blinding
will be ensured by (1) the medications being dispensed by
the hospital clinical trial pharmacy, (2) the use of an
identical active placebo tablet which mimics the side-
effects of amitriptyline and (3) questionnaire data that is
subjectively being taken by research assistants blinded to
group allocation.
Intervention
Participants in the intervention arm will receive a TCA,
25 mg of amitriptyline (Alphapharm Pty Ltd., Miller’s
Point, NSW, Australia), and those in the control arm will
receive an active placebo, 1 mg benztropine mesylate
(Phebra Pty Ltd., NSW, Australia). Amitriptyline and
benztropine will be administered in identical capsules to
be taken in a single dose at the same time each day. We
selected low-dose amitriptyline as it is commonly pre-
scribed for the management of chronic pain [19]. It has
been reported to be the most effective antidepressant for
the treatment of neuropathic pain, such as diabetic neur-
opathy and neuralgia [20], and is also effective for various
pain conditions, including fibromyalgia [7], ankylosing
spondylitis [21] and headaches [22]. Amitriptyline can act
on pain independent of depression [10], and while side
effects, such as dry mouth, mild constipation and fatigue,
can occur, lower doses are used for pain modification and
are generally well-tolerated. We have selected benztropine,
an active placebo, as it mimics the side effects of amitrip-
tyline, such as dry mouth and constipation, while having
no known effect on chronic pain [23, 24]. All participants
will be provided with usual care by their treating health
practitioners.
Study procedure
The study procedures are presented in Fig. 1. Potential
participants will be initially screened over the phone using
a questionnaire to determine whether they meet the eligi-
bility criteria. They will then attend an initial assessment
at Monash University Department of Epidemiology and
Preventive Medicine with the aim of obtaining informed
consent and confirming the individual’s eligibility to
participate in the trial. Eligible participants will be rando-
mised, complete a baseline assessment and receive the
first 3 months of amitriptyline or benztropine from the
Alfred Hospital Clinical Trials Pharmacy. Participants will
be contacted by phone at 2 weeks, 1–2 months, 3 months,
4–5 months and 6 months to monitor their progress and
any side effects of the treatment. The 3- and 6-month
outcome questionnaires and the second 3 months of
medication will be posted to the participants by mail. The
same researchers, who are blinded to treatment allocation,
will measure all clinical variables, administer question-
naires, monitor compliance and record adverse events.
Unblinding will be allowed under certain circumstances,
such as a participant’s physician requiring their allocated
intervention to ensure that they receive the appropriate
medical care. Compliance by trial medication will be
assessed by pill count. Participants will not be paid for
their participation in the trial, but they will be reimbursed
for parking and transport costs.
Outcome measures
The following primary and secondary, self-report outcome
measures will be administered by blinded research
assistants at baseline and 3 and 6 months.
Primary outcome measures: pain intensity
Our primary outcome measure will be pain intensity
measured at 6 months using a Visual Analogue Scale
(VAS) of 100 mm. However, the Descriptor Differential
Scale, a valid measure of pain intensity, will also be
assessed [25]. The Descriptor Differential Scale has been
used in a previous trial of antidepressants in low back
pain [15], enabling calculation of study sample size and
comparison of results.
Secondary outcome measures: disability, work absenteeism
and hindrance in work performance
Disability will be assessed using the Roland Morris
Disability Questionnaire [26], which is a validated
instrument designed to assess self-rated disability caused
by low back pain.
We will examine absenteeism and hindrance in
performance of paid and unpaid work using The Short
Form Health and Labour questionnaire (SFHLQ). The
SFHLQ is a validated questionnaire which examines
work absenteeism and hindrance in performance of paid
and unpaid work in relation to injury or sickness [27].
Other measures
Global improvement: a 6-point scale, ranging from 'no
change' to a 'great deal better' will be used to assess glo-
bal improvement [28].
General health status will be measured using the Euro-
Qol, 5 dimensions instrument (EQ-5D-5 L) [29].
Depression: severity of mood symptoms will be
assessed using the Beck Depression Inventory [30].
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Fear of movement/(re)injury will be examined using
the 17-item Tampa Scale [31].
Potential explanatory factors
Anthropometry
Height (stadiometer), weight (electric scales) and Body
Mass Index (height/weight2) will be measured at baseline.
Physical activity
The International Physical Activity Questionnaire short
version [32] will be used at baseline, and 3 and 6 months.
Concomitant medication use
The use of non-opioid analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) will be allowed during the
trial. The randomisation process is the most effective
method for ensuring that the two groups are as similar as
possible with respect to known confounders and unknown
potential confounders including treatments. We will also
adjust for medication use in the analyses.
Compensation status
For each individual we will record whether their back
pain is associated with a compensation claim, and if so
the nature of the claim, including the type, duration,
items approved and associated costs.
Monitoring
Adverse events will be monitored on a monthly basis
over the phone using a validated questionnaire, the UKU
Side Effects Rating Scale [33]. This questionnaire in-
volves a standardised, physician-administered interview
for assessing the severity and impact of side effects of
psychotropic drugs on daily function. The participants
will be requested to report any adverse events to the
research staff spontaneously. Details of major adverse
events and their relationship with study intervention will
be recorded and reported to the Ethics Committees. The
participants’ physician will also be notified of their
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Fig. 1 Trial flow diagram
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Sample size calculation
Reduction in pain intensity
A previous clinical trial of TCAs in individuals with
chronic low back pain reported the mean (standard devi-
ation (SD)) pain scores measured on the VAS to reduce to
5.70 (2.43) in the placebo group (n = 48) [34]. With n = 56
in each arm of the study, we have 90 % power to detect a
difference of 1.5 (i.e. VAS to reduce to 4.20 (2.43) in the
treatment group), which reflects the minimum clinically
significant reduction in pain intensity (α = 0.05, two-sided
significance).
In a recent study of individuals with low back pain,
the control group (n = 22) had a pain score that reduced
to a mean (SD) = 6.2 (2.8) on the Descriptor Differential
Scale following treatment, while the pain score of the
treatment group (TCA) (n = 19) reduced to a mean (SD)
score = 4.5 (2.6) [15]. With an α = 0.05 and n = 60 in
each arm of the study, we have 90 % power to detect a
difference of this size (1.7), which reflects clinically
significant reductions in pain intensity from ‘moderate’
to ‘mild’ or from ‘strong’ to ‘moderate’, which is equiva-
lent to a decrease of 2 units (17 %) on the Descriptor
Differential Scale (0–12 per descriptor) [35].
Improvement in disability
With 60 in each arm of the study, we will have 90 %
power to detect a clinically relevant difference in disabil-
ity (improvement of 13–16 % in disability or 3–4 points
on the 24-point Roland Morris Disability Questionnaire
after 26 weeks [36]) (α = 0.05, two-sided significance),
which corresponds to a significant improvement in key
functional activities, including walking and dressing.
More generally, with 60 per arm we have 90 % power
to detect a difference of 0.60 SDs. With our primarily
analyses involving adjustment for the baseline value of
the outcome, we will have greater than 90 % power ac-
cording to the size of the baseline-follow-up correlation.
Given our previous experience in such studies we expect
a maximum dropout rate of 20 % so we will recruit a
total of 150 (75 in each arm of the study) [37].
Statistical analysis
Summary statistics comparing randomised arms at baseline
will be tabulated. Intention-to-treat analyses of primary and
secondary continuous outcomes will be performed by linear
regression adjusting for the baseline of the outcome vari-
able where relevant. Logistic regression will be performed
for binary outcomes. Adjustment for imbalanced baseline
factors, including the presence of symptoms other than low
back pain, will be performed as supplementary analyses.
Analyses of treatment efficacy will be done by censoring
individuals at the time of any protocol deviation and
developing a model for the probability of deviation,
followed by weighted analyses using only the uncensored
individuals where the weights are the inverse probability of
censoring. This produces estimates of treatment effect as if
there was full compliance with the protocol in this RCT
and is far preferable to per-protocol analyses based on
(unweighted) observed compliance [38]. This RCT is
well-placed to model noncompliance with frequent
monitoring for adverse events and resultant prognostic
information.
Data integrity and management
All collected data will be recorded using Case Report
Forms or questionnaires and stored in a locked area in the
Department of Epidemiology and Preventive Medicine at
Monash University with secured and restricted access.
The electronic data will be stored in a password-protected
database with secured and restricted access. All data
collected will be kept strictly confidential. Data transfer
will be encrypted with all data deidentified. Only research
personnel on the project will have access to the study
data.
Withdrawal
If participants withdraw before completion of the study,
the reason and date will be recorded and participants
will be asked if they can complete the remaining
outcome measures.
Monitoring
The principal investigators will monitor the conduct and
progress of the project and ensure that all trial procedures
are compliant with the trial protocol. The research team
will have regular meetings to ensure efficient study
execution and ongoing monitoring of adverse events.
Discussion
We have proposed to conduct a pragmatic, double-
blind, randomised, placebo-controlled trial to investigate
whether low-dose amitriptyline is more effective than
placebo in the management of pain in individuals with
chronic low back pain. We will also investigate whether
lose-dose amitriptyline is more effective than placebo in
improving disability and minimising absenteeism and
hindrance with performance of paid/unpaid work. If
amitriptyline is found to be effective, it will provide
high-quality evidence for this therapeutic approach to
the management of chronic low back pain.
This current trial of amitriptyline for chronic low back
pain was designed to address some of the limitations of
previous RCTs which have been identified in meta-analyses.
The most up-to-date meta-analyses by the Cochrane
collaboration reported that a qualitative analysis of the trials
with a low risk of bias found conflicting evidence regarding
the effectiveness of antidepressants in the reduction of pain
for individuals with chronic low-back pain, while a meta-
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analysis of six trials showed no difference in pain relief
between antidepressants and placebo [14]. The review
highlighted a number of limitations including a paucity of
trials that examined antidepressants for the treatment of
pain, in particular those which used a low-dose antidepres-
sant. Moreover, small sample sizes, which can result in
insufficient statistical power to detect clinically relevant
effects, was a key limitation. Of the six trials identified in
the Cochrane meta-analysis examining the effect of low-
and high-dose antidepressants on pain, study populations
ranged from 18 to 92 (randomised) subjects. In this current
clinical trial we aim to recruit 150 subjects with chronic
low back pain. If successful, it will be the largest trial of an
antidepressant for the treatment of pain in participants with
low back pain to date. A further methodological issue that
was reported was the short follow-up periods of the trials
[14]. These periods were generally between 6 and 8 weeks;
however, one study followed up participants only until
4 weeks [39], while a single study extended to 12 weeks
[15]. We have selected to follow-up participants over
6 months to enable the efficacy of the low-dose antidepres-
sants to be examined over a longer time period.
Previous trials that have examined the efficacy of antide-
pressants for treating pain in low back pain have varied in
both the percentage of participants recruited with and
without depression and the severity of depression of the
included participants. While one study specifically selected
participants with overt symptoms of depression [34] and
two studies have included a mix of participants with and
without depression [39, 40], two studies excluded individ-
uals with major depression [15, 41] and, in a further study,
it was unclear whether participants had depression [42].
We have chosen to exclude potential participants with de-
pression or psychosis to allow us to examine the effective-
ness of low-dose amitriptyline specifically on pain. Finally,
we have chosen to use an active placebo, benztropine
mesylate. Only two of the previous studies used an active
placebo, with the remaining studies selecting a standard,
inactive placebo. The benefit of using benztropine mesylate
is that it mimics the side-effects of amitriptyline and assists
with blinding of participants.
This trial has several potential limitations that need to be
considered. Given that we are examining the effectiveness
of low-dose amitriptyline, which is a TCA, it is not possible
to directly extrapolate the findings to higher doses of TCAs
or other types of antidepressants. While a variety of differ-
ent types of antidepressants have been examined in the
management of low back pain, much of the investigation
has focused on TCAs and SSRIs. TCAs and SSRIs block
the absorption of the chemicals or neurotransmitters, sero-
tonin and/or noradrenaline, at the spine and midbrain [6].
There is preliminary evidence to suggest that low-dose
TCAs produce greater reduction in pain compared with
SSRIs and placebo. For instance, a study by Atkinson [15],
which performed a head-to-head comparison for TCAs
and SSRIs, showed an effect size of 0.31 (−0.23, 0.87) for
fluoxetine (SSRI) and −0.62 (1.24, −0.01) for desipramine
(TCA). This provides preliminary evidence suggesting that
low-dose TCAs produce greater reduction in pain
compared with placebo and SSRIs. However, this is still not
proven in the treatment of low back pain as meta-analyses
show no significant differences in pain between the TCA
and SSRI treatment groups [14].
The current trial will involve the recruitment of partici-
pants with chronic, nonspecific low back pain. While this
means that our population sample has the potential to be
heterogeneous in nature, the participants recruited will
represent a distinct clinical entity; that is they will have
pain that has been present for longer than 3 months, their
pain will be of no known cause and participants will have
no diagnosed psychosis or depression. A further limitation
of this trial relates to examining the adverse events associ-
ated with the use of low-dose antidepressants. While in
our evaluation of the effectiveness of amitriptyline we will
record the type, frequency and severity of adverse events
that occur during the trial, the study is not designed to
evaluate adverse events and prospective cohort studies
with larger sample sizes are needed to examine the
incidence of adverse events.
In summary, low back pain is the leading cause of
disability worldwide, but effective treatment approaches are
limited. Low-dose antidepressants are commonly used in
clinical practice to treat pain in individuals with chronic
low back pain; however, their use is unproven. This RCT
will provide high-quality evidence to investigate whether
low-dose amitriptyline is an effective treatment in the
management of low back pain. If amitriptyline is found to
be effective, it could be used to reduce pain, disability and
work absenteeism and hindrance of work performance in
individuals with chronic low back pain, and in turn, reduce
the need for treatments and surgery that result in substan-
tial costs to the community.
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